Tamtuvetmab (AT-005), a caninised version of blontuvetmab targeting CD52, enhances progression-free survival (PFS) and demonstrates in vivo efficacy for treating naive T-cell lymphoma (LSA) in dogs. The compound has received veterinary approval [1] [2].
CAS Number:
[1608122-71-9]
Target:
NF-kappaB
* VAT and and shipping costs not included. Errors and price changes excepted
